Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
METHYLPREDNISOLONE , ACETYLCYSTEINE
The George Institute
Acute Alcoholic hepatitis
1 trial -
METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab
Genmab A/S
Non-Small Cell Lung Cancer
1 trial -
METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE
Novartis Pharmaceuticals
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
1 trial -
MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL
Pari Pharma GmbH
Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.
1 trial -
MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL
Lacuna Pharma Pty Ltd
General anaesthesia
1 trial -
MIDAZOLAM, DEXMEDETOMIDINE EVER PHARMA 100 microgrammes/mL, solution Γ diluer pour perfusion
Pari Pharma GmbH
Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation
1 trial -
MIE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Carcinoma
1 trial -
MITOMYCIN , JNJ-42756493, GEMCITABINE
Janssen-Cilag International N.V.
High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations
1 trial -
MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084
Merck Sharp and Dohme
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
1 trial -
MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL
Merck Sharp and Dohme
Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10
1 trial -
MK-2870, PACLITAXEL , -, PARACETAMOL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , CISPLATIN , GEMCITABINE , -, PEMETREXED
Merck Sharp and Dohme
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])
1 trial -
MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE
Merck Sharp and Dohme
Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.
1 trial -
MK-8527
Merck KGaA, Darmstadt, Germany
Human Immunodeficiency Virus (HIV)
1 trial -
MORPHINE SULFATE, KETAMINE, FENTANYL CITRATE, SODIUM CHLORIDE, SODIUM CHLORIDE
Pari Pharma GmbH
urgency, limb injuries
1 trial -
MTX
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gestational Trophoblastic Tumor
1 trial -
MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Adult patients (age β₯18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naΓ―ve.
1 trial -
MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringeβ―, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL
Novartis Pharmaceuticals
Lupus nephritis
1 trial -
MabThera 500 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Glofitamab, RoActemra 20 mg/mL concentrate for solution for infusion
Hoffmann-La Roche
Relapsed or refractory diffuse large B-cell lymphoma
1 trial -
MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN
Hoffmann-La Roche
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
1 trial -
Magnesium Pantoprazole
Takeda
GERD
1 trial -
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study
The George Institute
Maintenance treatment in metastatic non-squamous lung cancer
1 trial -
Maridebart cafraglutide
Amgen
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
1 trial -
Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg
The George Institute
Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources